These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 29847322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Investigational drugs in phase I and phase II clinical trials for thalassemia.
    Motta I, Scaramellini N, Cappellini MD.
    Expert Opin Investig Drugs; 2017 Jul; 26(7):793-802. PubMed ID: 28540737
    [Abstract] [Full Text] [Related]

  • 7. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O, Komrokji RS.
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [Abstract] [Full Text] [Related]

  • 8. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C, Syed YY.
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
    Mies A, Hermine O, Platzbecker U.
    Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
    [Abstract] [Full Text] [Related]

  • 11. Managing anaemia in bone marrow failure syndromes.
    Narayanan S.
    Curr Opin Support Palliat Care; 2018 Dec; 12(4):538-541. PubMed ID: 30299326
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [Abstract] [Full Text] [Related]

  • 15. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
    Gupta N, Wish JB.
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
    [Abstract] [Full Text] [Related]

  • 16. Investigational therapies for renal disease-induced anemia.
    Schmid H, Jelkmann W.
    Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
    [Abstract] [Full Text] [Related]

  • 17. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W.
    Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
    Martinez PA, Li R, Ramanathan HN, Bhasin M, Pearsall RS, Kumar R, Suragani RNVS.
    J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
    [Abstract] [Full Text] [Related]

  • 20. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
    Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, Raymon HK, Heise C, Daniel T, Chopra R, Sung V.
    Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.